Semaglutide once weekly in people with type 2 diabetes: Real-world analysis of the Canadian LMC diabetes registry (SPARE study).

Diabetes, Obesity & Metabolism
Ruth E BrownRonnie Aronson

Abstract

To investigate real-world short-term clinical outcomes in adults with type 2 diabetes (T2D) who initiated semaglutide in a specialist endocrinology practice in Canada. This study was a retrospective observational study using data from the Canadian LMC Diabetes Registry. Adults with T2D who were naïve to glucagon-like peptide-1 receptor agonist (GLP-1RA) therapy, initiated semaglutide therapy as usual standard of care between February 2018 and February 2019, and maintained semaglutide therapy during follow-up, were eligible for analysis. The primary outcome was mean change in glycated haemoglobin (HbA1c) at 3- to 6-month follow-up. In the final analytical cohort (n = 937), there was a statistically significant mean ± SD reduction in HbA1c of -1.03 ± 1.24% (11.3 ± 13.6 mmol/mol, P < 0.001) and weight of -3.9 ± 4.0 kg (P < 0.001), with no significant change in self-reported incidence of hypoglycaemia. There was a significant reduction in HbA1c and weight regardless of number of co-therapies or semaglutide dose. However, adults using the 1.0-mg dose had a significantly greater reduction in HbA1c compared to adults using the 0.25- to 0.5-mg dose (between-group difference - 0.24 ± 0.06%, 2.6 ± 0.7 mmol/mol; P < 0.001). Adults using b...Continue Reading

References

Dec 1, 2011·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Chrysi Koliaki, John Doupis
Dec 14, 2016·The New England Journal of Medicine·Rachel E ShermanRobert M Califf
Feb 6, 2018·The Lancet. Diabetes & Endocrinology·Richard E PratleyUNKNOWN SUSTAIN 7 investigators
Apr 25, 2018·The Journal of Clinical Endocrinology and Metabolism·Helena W RodbardPaul Norwood
Oct 14, 2019·Diabetes & Metabolism·E Goncalves, D S Bell

❮ Previous
Next ❯

Citations

Feb 11, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·David M WilliamsThinzar Min
Nov 19, 2020·Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy·Mario Luca MorieriGian Paolo Fadini
Jun 3, 2021·International Journal of Environmental Research and Public Health·Carlos MorillasJosé Luis Gorriz
Jul 27, 2021·Frontiers in Endocrinology·Mark M Smits, Daniël H Van Raalte
Jul 23, 2021·Diabetic Medicine : a Journal of the British Diabetic Association·Katrine B HansenHenrik Vestergaard
Sep 26, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Patrick HolmesThozhukat Sathyapalan

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT04175665

Software Mentioned

SAS

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.

Related Papers

The Annals of Pharmacotherapy
Nicholas W Carris, Eric A Dietrich
Clinical Diabetes : a Publication of the American Diabetes Association
Sally Hughes, Joshua J Neumiller
Clinical Diabetes : a Publication of the American Diabetes Association
Vinh Bui, Joshua J Neumiller
© 2022 Meta ULC. All rights reserved